S&P/ASX 200 Index (ASX: XJO) shares are down 0.4% after the US cancelled a trip for officials to the Middle East over the weekend.
There is currently no prospect of fresh peace talks between the US and Iran.
The US blockade of Iranian ports remains in place, and Iran says it will not negotiate under these circumstances.
Meanwhile, on the The Bull this week, two experts have revealed their views on three ASX 200 shares.
Let's see what they think.
Image source: Getty Images
Pro Medicus Ltd (ASX: PME)
The Pro Medicus share price is $137.45, down 0.6% at the time of writing and down 51% over the past six months.
Pro Medicus sells proprietary medical imaging software and services to healthcare providers worldwide.
The Pro Medicus share price hit a record of $336 last July before commencing a steep decline alongside the broader healthcare sector.
Stuart Bromley from Medallion Financial Group has a buy rating on this ASX 200 healthcare share.
Bromley said:
The share price is down significantly in the past year on fears of artificial intelligence impacting the business.
But the company continues winning large and long term contracts. PME recently renewed a five-year, $37 million contract with Northwestern Medicine based in Chicago. The renewal comes with increased minimums and a higher fee per transaction.
In our view, PME presents a rare chance to buy a world class software play at a significant discount.
Life360 Inc (ASX: 360)
The Life360 share price is $21, up 0.7% at the time of writing and down 58% over six months.
ASX 200 tech shares experienced a major rout between 29 August 2025 and 30 March this year.
AI fears drove a 48% cliff-dive in the S&P/ASX 200 Information Technology Index (ASX: XIJ) over that 7-month period.
A strong turnaround in the Australian and US share markets began on 31 March. Since then, Life360 shares have risen 15.6%.
Jonathan Tacadena from MPC Markets thinks investors should keep Life360 shares on their watchlist for the moment.
Tacadena said:
In our view, fears of artificial intelligence severely impacting software-as a-service companies are fading, and a lot of our preferred names have rebounded strongly. We expect Life360's share price to recover further moving forward.
Full year revenue in 2025 was up 32 per cent on the prior corresponding period. It expects revenue growth in full year 2026 to be driven by its core subscription business and the scaling of its advertising platform.
A2 Milk Company Ltd (ASX: A2M)
The A2 Milk share price is $7.32, down 1.1% at the time of writing and down 22% in just one month.
This sharp fall followed a trading update revealing higher supply chain costs associated with the Iran war, and other matters.
Tacadena has a sell rating on the ASX 200 consumer staples share.
The analyst said:
This infant formula company recently downgraded guidance in full year 2026 in response to the Middle East conflict indirectly generating supply chain issues.
It expects lower infant milk formula sales, mostly related to Chinese labels.
The EBITDA percentage margin is forecast to decline from previous guidance of between 15.5 per cent to 16 per cent to between 14 per cent to 14.5 per cent. Net profit after tax is expected to be similar or down on full year 2025.
Tacadena noted that the A2 Milk share price has fallen from $9.24 on 10 April to $7.32 today.
It may be prudent to reduce risk and deploy capital elsewhere in case the downward trend continues from here.
